Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MAGE A3 TCR

Next Previous
Drug Profile

MAGE A3 TCR

Alternative Names: Anti-MAGE A3 HLA-A-01-restricted TCR; Anti-MAGE-A3-DP4-TCR; Anti-MAGE-A3-TCR

Latest Information Update: 31 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Cancer Institute (USA)
  • Developer Kite Pharma; National Cancer Institute (USA)
  • Class Antineoplastics; Cell therapies; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 24 Mar 2021 National Cancer Institute completes a phase I/II trial in Solid tumours (Second-line therapy or greater, Combination therapy, Late-stage disease) in USA (NCT02111850)
  • 04 Oct 2019 MAGE-A3 TCR is still in phase I/II trials for Solid tumours (Second-line therapy or greater, Combination therapy, Late-stage disease) in USA (IV) (NCT02111850)
  • 03 Oct 2017 Kite Pharma has been acquired by Gilead Sciences

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top